Leerink maintains Outperform on BridgeBio Oncology Thera, cuts PT to $27
Leerink Partners maintained BridgeBio Oncology Thera at Outperform and cut its price target to $27.00 per share from $39.00, according to a ratings-action report.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.